Document Type
Article
Publication Date
5-8-2023
Abstract
Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not require immediate therapy, and the time from diagnosis-to-treatment interval can be highly variable with no universal criteria to initiate systemic therapy. Hence, we sought to evaluate the prognostic relevance of early relapse or progression within 24 months from systemic therapy initiation in a large US cohort. The primary objective was to evaluate the overall survival (OS) in the two groups. The secondary objective included the evaluation of factors predictive of POD24 and the assessment of cumulative incidence of histologic transformation (HT) in POD24 versus non-POD24 groups. The study included 524 patients with 143 (27%) in POD24 and 381 (73%) in non-POD24 groups. Patients with POD24 had inferior OS compared to those without POD24, regardless of the type of systemic therapy received (rituximab monotherapy or immunochemotherapy) at diagnosis. After adjusting for factors associated with inferior OS in the univariate Cox model, POD24 remained associated with significantly inferior OS (HR = 2.50, 95% CI = 1.53-4.09, p = 0.0003) in multivariable analysis. The presence of monoclonal protein at diagnosis and those who received first-line rituximab monotherapy had higher odds of POD24 on logistic regression analysis. Patients with POD24 had a significantly higher risk for HT compared to those without POD24. POD24 in MZL might be associated with adverse biology and could be used as an additional information point in clinical trials and investigated as a marker for worse prognosis.
Recommended Citation
Epperla, Narendranath; Welkie, Rina Li; Torka, Pallawi; Shouse, Geoffrey; Karmali, Reem; Shea, Lauren; Anampa-Guzmán, Andrea; Oh, Timothy S; Reaves, Heather; Tavakkoli, Montreh; Lindsey, Kathryn; Greenwell, Irl Brian; Hansinger, Emily; Thomas, Colin; Chowdhury, Sayan Mullick; Annunzio, Kaitlin; Christian, Beth; Barta, Stefan K; Geethakumari, Praveen Ramakrishnan; Bartlett, Nancy L; Herrera, Alex F; Grover, Natalie S; and Olszewski, Adam J, "Impact of Early Relapse within 24 Months after First-Line Systemic Therapy (POD24) on Outcomes in Patients with Marginal Zone Lymphoma: A US Multisite Study" (2023). Department of Medicine Faculty Papers. Paper 410.
https://jdc.jefferson.edu/medfp/410
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
37158890
Language
English
Comments
This article is the author's final published version in Journal of Hematology & Oncology, Volume 16, Issue 1, 2023, Article number 49.
The published version is available at https://doi.org/10.1186/s13045-023-01448-y.
Copyright © The Author(s) 2023
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.